financetom
Business
financetom
/
Business
/
Deckers Outdoor Fiscal Q2 Earnings, Sales Rise; Fiscal 2026 Outlook set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deckers Outdoor Fiscal Q2 Earnings, Sales Rise; Fiscal 2026 Outlook set
Oct 23, 2025 2:19 PM

04:46 PM EDT, 10/23/2025 (MT Newswires) -- Deckers Outdoor ( DECK ) reported fiscal Q2 earnings late Thursday of $1.82 per diluted share, up from $1.59 a year earlier.

Analysts polled by FactSet expected $1.58.

Net sales for the quarter ended Sep. 30 were $1.43 billion, up from $1.31 billion a year earlier.

Analysts surveyed by FactSet expected $1.42 billion.

The company expects fiscal 2026 EPS of $6.30 to $6.39 and net sales of approximately $5.35 billion. Analysts expect EPS of $6.33 on sales of $5.46 billion.

Shares of Deckers Outdoor ( DECK ) were down over 8% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Argonautic Ventures Says Preliminary Non-Binding Proposal To Benson Hill's Board Related To Proposed Acquisition By To-Be-Formed Acquisition Vehicle
BRIEF-Argonautic Ventures Says Preliminary Non-Binding Proposal To Benson Hill's Board Related To Proposed Acquisition By To-Be-Formed Acquisition Vehicle
Jun 27, 2024
June 27 (Reuters) - Benson Hill Inc ( BHIL ): * ARGONAUTIC VENTURES - PRELIMINARY NON-BINDING PROPOSAL TO BENSON HILL'S BOARD RELATED TO PROPOSED ACQUISITION BY TO-BE-FORMED ACQUISITION VEHICLE * ARGONAUTIC VENTURES-PROPOSAL TO BENSON HILL'S BOARD RELATED TO PROPOSED ACQUISITION ALL OF OUTSTANDING SHARES FOR CASH CONSIDERATION OF $0.2236/SHARE Source text for Eikon: Further company coverage: ...
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Jun 27, 2024
June 27 (Reuters) - Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday. The U.S. health regulator's assent on Wednesday for the therapy, branded as Ohtuvayre, provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary...
Andlauer Healthcare to Launch Normal Course Issuer Bid
Andlauer Healthcare to Launch Normal Course Issuer Bid
Jun 27, 2024
09:00 AM EDT, 06/27/2024 (MT Newswires) -- Andlauer Healthcare Group ( ANDHF ) said Thursday that it secured TSX approval for a normal course issuer bid (NCIB) for up to 10% of its public float over the next 12 months. The company said it can purchase its shares for cancellation beginning on July 2 and until July 1, 2025. Andlauer...
Spice maker McCormick beats quarterly results on strong EMEA business
Spice maker McCormick beats quarterly results on strong EMEA business
Jun 27, 2024
(Reuters) - McCormick ( MKC ) beat market expectations for second-quarter profit and sales on Thursday, led by strong demand for its spices and seasonings in Europe, Middle East and Africa. Customers grappling with still-high costs preferred cooking at home to dining out, improving volumes across the company's consumer segment, its biggest unit. Consumer sales in Europe, Middle East and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved